ArticleJournal of cachexia, sarcopenia and muscle2013
A pilot study of temsirolimus and body composition.
Article in Journal of cachexia, sarcopenia and muscle, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.Nutrients · 2023Pooled it
- Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.PloS one · 2023Pooled it
- The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review.Aging clinical and experimental research · 2022Pooled it
- The assessment and impact of sarcopenia in lung cancer: a systematic literature review.BMJ open · 2014Pooled it
- Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs & aging · 2024Article
- The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels.European geriatric medicine · 2022Article
- Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.Oncotarget · 2020Article
- Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Observational
- Chemotherapy-Induced Sarcopenia.Current treatment options in oncology · 2020Review
- Muscle wasting associated with the long-term use of mTOR inhibitors.Molecular and clinical oncology · 2016Article
- Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib.Journal of cachexia, sarcopenia and muscle · 2015Article
- Muscle wasting: an overview of recent developments in basic research.Journal of cachexia, sarcopenia and muscle · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBody weight and composition play a role in cancer etiology, prognosis, and treatment response. Therefore, we analyzed the weight, body composition changes, and outcome in patients treated with temsirolimus, an mTor inhibitor that has weight loss as one of its side effects. PATIENTS AND
methodsSixteen patients with advanced solid tumors treated with temsirolimus were studied; body composition was evaluated utilizing computerized tomography images. Sarcopenia was defined as skeletal muscle index lower than 38.5 cm(2)/m(2) for women and 52.4 cm(2)/m(2) for men.
resultsFive of 16 patients (31 %) were men; median age, 60 years. Forty-four percent (7/16) of patients were sarcopenic. Fatigue, anemia, hyperglycemia, and hyperlipidemia were common. Baseline sarcopenia and body composition did not correlate with worse toxicity or treatment outcome. However, there was a trend for greater loss of adipose area (p = 0.07), fat mass (p = 0.09), and adipose index (p = 0.07) for patients with grade 3 or 4 toxicities versus those with grade 1 and 2 side effects.
conclusionPatients with higher grade toxicities tended to lose more body fat, suggesting a possible end-organ metabolic effect of temsirolimus. These observations merit exploration in a larger cohort of patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.